Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Warfarin in AF and Mitral Stenosis
NCT03673605Phase 4Withdrawn
- Sponsor
- PharmEvo
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) and mitral valve stenosis (2 arms), sponsored by PharmEvo. Primary endpoint: Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging at 12 months. Planned start Dec 2016; status: withdrawn.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)mitral valve stenosis
Beyond the preview
Go deeper on NCT03673605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673605.